🇺🇸 AMGN — Amgen Inc.

Healthcare Compra
← Volver

Precio actual

437,23 USD

Máx. histórico

447,03

10 días

Caída desde máximo

-2,19%

Rango 52 semanas

269,77 – 447,03

Variación hoy

-1,55%

Cierre anterior

444,12

Rango de hoy

435,01 – 441,66

Volumen hoy

1.615.172

Información
Nombre completo
Amgen Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Healthcare
Industria
Drug Manufacturers - General
Empleados
31.500
PER ⓘ
27,17 (puede no estar actualizado)
Dividend yield
2,27% (puede no estar actualizado)
Precio objetivo analistas
389,69 USD (puede no estar actualizado)
Primera cotización
17/06/1983
Precio actualizado
hace 1 día
Sobre la empresa

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Dividendos repartidos Total últimos 12 meses: 9,9400 USD · Yield: 2,27%
Fecha de pago Importe por participación
21/08/2026 2,5200 USD
15/05/2026 2,5200 USD
13/02/2026 2,5200 USD
21/11/2025 2,3800 USD
22/08/2025 2,3800 USD
16/05/2025 2,3800 USD
14/02/2025 2,3800 USD
18/11/2024 2,2500 USD
16/08/2024 2,2500 USD
16/05/2024 2,2500 USD
15/02/2024 2,2500 USD
16/11/2023 2,1300 USD
17/08/2023 2,1300 USD
17/05/2023 2,1300 USD
14/02/2023 2,1300 USD
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
08/09/2023 255,75 260,34 254,97 259,43 +1,98% 2,10% 2.449.000
07/09/2023 250,54 254,70 250,40 254,39 +2,16% 1,72% 2.228.300
06/09/2023 254,44 254,44 248,38 249,01 -1,97% 2,38% 1.988.900
05/09/2023 256,71 257,39 253,92 254,01 -1,05% 1,35% 1.763.600
01/09/2023 258,68 259,03 256,10 256,71 +0,14% 1,13% 1.350.200
31/08/2023 258,22 259,00 256,29 256,34 -0,60% 1,05% 2.065.000
30/08/2023 260,00 260,87 256,95 257,88 -0,68% 1,51% 1.694.300
29/08/2023 257,36 259,85 256,82 259,64 +1,20% 1,18% 2.216.600
28/08/2023 256,96 258,12 255,14 256,55 +0,07% 1,16% 1.661.300
25/08/2023 257,11 257,74 254,81 256,38 -0,09% 1,14% 1.786.600
24/08/2023 256,73 260,19 256,17 256,62 -0,29% 1,57% 1.888.900
23/08/2023 259,50 259,85 255,98 257,36 -0,10% 1,49% 2.256.800
22/08/2023 260,24 260,40 257,35 257,62 -1,18% 1,17% 1.720.300
21/08/2023 261,58 262,47 259,01 260,70 -0,43% 1,32% 2.324.100
18/08/2023 262,61 262,99 261,07 261,82 -0,77% 0,73% 2.814.500
17/08/2023 263,87 266,58 263,27 263,85 -0,44% 1,25% 2.256.100
16/08/2023 266,33 268,24 264,58 265,02 -0,37% 1,37% 2.244.000
15/08/2023 261,32 266,63 259,96 266,01 +1,93% 2,55% 2.781.200
14/08/2023 262,22 263,47 259,85 260,97 -0,59% 1,38% 1.966.100
11/08/2023 261,70 264,11 260,83 262,51 +0,17% 1,25% 1.560.600
10/08/2023 261,54 264,78 260,46 262,06 +1,06% 1,65% 1.919.200
09/08/2023 259,92 263,77 259,12 259,32 -0,57% 1,79% 2.428.100
08/08/2023 257,52 263,79 256,50 260,80 +3,11% 2,83% 5.321.600
07/08/2023 244,25 253,82 243,46 252,94 +3,97% 4,24% 4.076.600
04/08/2023 237,91 246,42 237,00 243,28 +5,45% 3,96% 5.181.200
03/08/2023 230,79 231,10 228,21 230,70 +0,13% 1,25% 2.322.200
02/08/2023 232,72 233,03 228,70 230,41 -0,74% 1,86% 2.593.500
01/08/2023 234,93 235,38 230,59 232,12 -0,87% 2,04% 1.843.400
31/07/2023 236,48 236,48 233,02 234,15 -0,94% 1,46% 2.826.600
28/07/2023 236,82 238,18 235,09 236,37 +0,14% 1,30% 1.889.500